| Abstract | All infants, including premature infants as young as 24 weeks' gestational age, are able to maintain an intragastric pH below 4 from the first day of life. By 24 weeks, maximal acid output approaches that in adults. In adult studies, proton pump inhibitors (PPIs) are highly effective in relieving reflux symptoms and healing reflux esophagitis. Studies are needed to evaluate PPI efficacy and appropriate dosing in infants and children. Consequences such as hypergastrinemia, bacterial overgrowth, and other potential adverse events associated with long-term PPI use also warrant evaluation in the pediatric population. |
| Authors | John T Boyle
(Affiliation: Children's Hospital of Greenville Hospital System, University of South Carolina School of Medicine, Greenville, South Carolina, USA. jboyle at ghs.org)
|
| Journal | Journal of pediatric gastroenterology and nutrition
(J Pediatr Gastroenterol Nutr)
2003 Nov-Dec
Vol. 37 Suppl 1
Pg. S12-6
ISSN: 0277-2116 United States |
| PMID | 14685072
(Publication Type: Journal Article, Review)
|
| Chemical References |
- Anti-Ulcer Agents
- Proton Pumps
|
| Topics |
- Adolescent
- Adult
- Anti-Ulcer Agents
(adverse effects, therapeutic use)
- Child
- Child, Preschool
- Esophagitis, Peptic
(drug therapy)
- Female
- Gastric Acid
(secretion)
- Gastroesophageal Reflux
(drug therapy)
- Humans
- Infant
- Male
- Proton Pumps
(adverse effects, antagonists & inhibitors)
- Treatment Outcome
|
